Satellos Bioscience Inc. to Present at Healthcare Investor Conference

Satellos Bioscience Inc. announced its participation in the Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026. CEO Frank Gleeson will present on April 21, followed by one-on-one meetings with CFO Liz Williams. The company is developing SAT-3247, an oral small molecule therapy for degenerative muscle diseases like Duchenne Muscular Dystrophy (DMD), targeting AAK1 to restore natural muscle repair and regeneration. SAT-3247 is currently in two Phase II clinical trials (BASECAMP for pediatrics and TRAILHEAD for adults). The company plans to explore further applications of SAT-3247 in other muscle-related conditions.